Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA/EP versus EMA/CO or TP/TE-based treatment strategy for high-risk or drug-resistant gestational trophoblastic neoplasia
ChiCTR2000037542Phase 3Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etoposide, methotrexate, actinomycin D, cisplatin, cyclophosphamide and 2 more in trophoblastic tumour (2 arms), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoints: human chorionic gonadotropin (hCG) and complete remission rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
etoposidemethotrexateactinomycin Dcisplatincyclophosphamide
03
Conditions
trophoblastic tumour
Beyond the preview
Go deeper on ChiCTR2000037542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037542.